NCT03340766 - Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

November 6, 2020

Study Completion Date

August 14, 2023

Conditions

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG

Blinatumomab

Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.

DRUG

Pembrolizumab

One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.

Trial Locations (22)

2010

Research Site, Darlinghurst

2065

Research Site, St Leonards

3002

Research Site, East Melbourne

3004

Research Site, Melbourne

3220

Research Site, Geelong

5000

Research Site, Adelaide

6150

Research Site, Murdoch

28046

Research Site, Madrid

29424

Research Site, Charleston

29607

Research Site, Greenville

37007

Research Site, Salamanca

39008

Research Site, Santander

44035

Research Site, Nantes

69120

Research Site, Heidelberg

69495

Research Site, Pierre-Bénite

89081

Research Site, Ulm

94010

Research Site, Créteil

97080

Research Site, Würzburg

92093-0960

Research Site, La Jolla

6229 HX

Research Site, Maastricht

3015 CN

Research Site, Rotterdam

08025

Research Site, Barcelona